OTC · Health care

Galera Therapeutics, Inc. (GRTXD)

At March 31, 2026 it held $5.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on May 14, 2026.

Watch GRTXD in 60 seconds

Price

$18.99

+21.58% on the day · August 3, 2026

52-week range $3.02 to $30.00

Market cap

$3B

P/E

29.7

on FY2025 diluted EPS

What Galera Therapeutics, Inc. does

Galera Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker GRTXD.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$2.5M	$149M	$0.64	n/a
2024	n/a	-$20.2M	-$19M	-$0.34	-$12.1M
2023	n/a	-$49.3M	-$59.1M	-$1.33	-$44.9M
2022	n/a	-$51.2M	-$62.2M	n/a	-$43.5M
2021	n/a	-$73.4M	-$80.5M	-$3.12	-$68.2M
2020	n/a	-$70.6M	-$74.2M	-$2.98	-$60M

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Galera Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 4, 2026
Deregistration 15-12G
August 4, 2026
Form POS AM filing POS AM
August 4, 2026
Form S-8 POS filing S-8 POS
August 4, 2026
Form S-8 POS filing S-8 POS
August 4, 2026
Change in control 8-K
July 31, 2026
Unregistered share sale 8-K
July 13, 2026
Form DEFA14C filing DEFA14C
July 13, 2026
Shareholder rights changed 8-K
July 7, 2026
Form DEFA14C filing DEFA14C

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 5, 2026. Insider transactions on SEC

Insider trades

What the people running Galera Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
August 3, 2026	Friedman Michael R.Director	Other changeindirect	41,631	-	-	Form 4
August 3, 2026	Alleva Lawrence MDirector	Other change	11	-	-	Form 4
August 3, 2026	Alleva Lawrence MDirector	Other changeindirect	40	-	-	Form 4
August 3, 2026	Chang Nancy TDirector, 10% owner	Other change	47,434	-	-	Form 4
August 3, 2026	Sorensen MelPresident and CEO, Director	Other change	975	-	-	Form 4
May 15, 2026	Friedman Michael R.Director	Exercised optionsindirect	2,989,399	-	-	Form 4
May 15, 2026	Chang Nancy TDirector, 10% owner	Exercised options	661,309	-	-	Form 4
May 15, 2026	Emerald Bioventures, LLC10% owner	Exercised options	20,813,818	-	-	Form 4
April 7, 2026	Chang Nancy TDirector, 10% owner	Exercised options	1,180,611	-	-	Form 4
April 7, 2026	Friedman Michael R.Director	Exercised optionsindirect	5,336,870	-	-	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns GRTXD

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Emerald Bioventures, LLC13D, may seek influence with 1 related filers	30.2%	61,029,978	May 29, 2026
Parvinder Singh Hyare13D, may seek influence	6.65%	13,521,921	June 11, 2026
Chang Nancy T13D, may seek influence	5.9%	8,921,543	April 10, 2026

Latest filings below 5%: Ikarian Capital, LLC 0% (August 14, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 61,029,978 shares in total, about $1.16B at the last price.

Holder	Shares	As of
Emerald Bioventures, LLC10% owner	61,029,978	May 15, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about GRTXD

What does Galera Therapeutics, Inc. do?

Galera Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker GRTXD.

Is Galera Therapeutics, Inc. profitable?

Yes. Over the twelve months to March 31, 2026 it reported net income of $149M.

When did Galera Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on May 14, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the passive stake changed from August 14, 2026.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare GRTXD with

Compare GRTXD with any company

Follow GRTXD

Get an email when Galera Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow GRTXD: get an email when it files

Where the numbers come from

Financial figures are the values Galera Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.